文献速递中枢神经肿瘤放疗放疗物理与技术

去甲肾上腺素能激动剂作为放射性认知衰退的治疗机会

Noradrenergic Agonists as Treatment Opportunity of Radiation-Induced Cognitive Decline.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-07-20

该研究在小鼠颅脑照射10 Gy模型中发现,去甲肾上腺素能激动剂瑞波西汀(REB)或阿替美唑(ATI)可减轻辐射诱导的海马毒性,REB还能防止海马体积丢失并改善记忆功能障碍,提示NA治疗可能用于儿童脑肿瘤幸存者的远期并发症。

要点

  • REB和ATI可减轻辐射诱导的海马细胞凋亡、微胶质炎症并保留pCREB和BDNF表达。
  • REB治疗可防止辐射后海马体积丢失并改善记忆功能障碍。
  • NA治疗可能针对儿童脑肿瘤幸存者放疗后的长期认知并发症。

核心结论

  • 去甲肾上腺素能激动剂REB和ATI可减轻辐射诱导的海马损伤,REB还能改善辐射诱导的记忆功能障碍。

研究设计与样本

  • 小鼠在出生后第22天接受10 Gy颅脑照射,并接受去甲肾上腺素能激动剂瑞波西汀(REB)或阿替美唑(ATI)治疗。
  • 在照射后6小时、1周和1个月进行组织学检查,检测海马细胞死亡、pCREB和BDNF表达、NSCs/NPCs丢失及微胶质炎症。
  • 照射后1个月通过行为测试组合和离体磁共振成像评估记忆缺陷和海马萎缩。

主要发现

  • REB和ATI显著减轻辐射诱导的海马毒性,减少辐射诱导的凋亡和微胶质炎症,并保留海马pCREB和BDNF表达。
  • 治疗还减轻海马NSCs/NPCs和未成熟神经元的丢失。
  • 放疗后观察到显著的海马体积丢失,REB治疗可防止该丢失。
  • 行为测试显示REB治疗成功减轻辐射诱导的记忆功能障碍。

临床怎么用

  • REB可能用于减轻儿童脑肿瘤患者颅脑放疗后的海马损伤和记忆功能障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pediatric patients undergoing cranial irradiation are at risk of developing neurocognitive impairments, with radiation-induced damage to the hippocampi playing a central role in this process. This damage is primarily driven by loss of neural stem/progenitor cells (NSCs/NPCs) and neuroinflammation. Noradrenergic agonists can potentially protect against radiation-induced hippocampal damage by reducing cell death and neuroinflammation. This study aims to assess whether pharmacologic boosting of noradrenaline (NA) can reduce radiation-induced hippocampal injury and prevent memory decline. MATERIALS AND METHODS: Mice were exposed to cranial irradiation of 10 Gy at postnatal day 22, and treated with noradrenergic agonists, reboxetine (REB), or atipamezole (ATI). At 6 hours, 1 week, and 1 month postirradiation, hippocampal cell death, phosphorylated cAMP responsive element-binding protein (pCREB), and brain-derived neurotrophic factor (BDNF) expression, loss of hippocampal NSCs/NPCs, and microglial inflammation were histologically investigated. At 1 month postirradiation, memory deficits and hippocampal atrophy were investigated by a behavioral test battery and ex vivo magnetic resonance imaging, respectively. RESULTS: We report that REB and ATI significantly mitigate radiation-induced hippocampal toxicity. Treatment with noradrenergic agonists reduces radiation-induced apoptosis, microglial inflammation, and preserves pCREB and BDNF expression in the hippocampus early after irradiation. It also attenuates the loss of hippocampal NSCs/NPCs and immature neurons. After radiation therapy, considerable hippocampal volume loss is observed, which is prevented by REB treatment. Finally, behavioral testing revealed that REB treatment after radiation therapy successfully mitigates radiation-induced memory dysfunction. CONCLUSIONS: The present findings uncover the marked benefits of NA treatment against radiation-induced hippocampal injury. We demonstrate that REB is able to mitigate radiation-induced memory dysfunction, which highlights the potential of NA treatment for addressing long-standing complications faced by pediatric brain tumor survivors.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. De Bie I, Primac I, Berden L, et al. Noradrenergic Agonists as Treatment Opportunity of Radiation-Induced Cognitive Decline. Int J Radiat Oncol Biol Phys. 2025. PMID: 40695366. doi:10.1016/j.ijrobp.2025.07.1426

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。